Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention, epidemiology, diagnosisJulie Figoni, Pierre Tattevin, Catherine Chirouze et al.|Médecine et Maladies Infectieuses|2019Cited by 91
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulationOlivier Kosmider, Benjamin Terrier, G. Le Guenno et al.|Nature Communications|2024Cited by 87
Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosisB. Jaulhac, Pierre Tattevin, A. Saunier et al.|Médecine et Maladies Infectieuses|2019Cited by 87
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare databaseLaurent Mortier, Philippe Saïag, Astrid Blom et al.|European Journal of Cancer|2024Cited by 8
Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.A. Blom Fily, Philippe Saïag, Laurent Mortier et al.|Journal of Clinical Oncology|2023Cited by 3